Carl Zeiss Meditec (ETR:AFX) stock price target upped to 36.00EUR, reported earlier today by HSBC
- Updated: September 18, 2016
Carl Zeiss Meditec (ETR:AFX) had its estimated target price bumped up to 36EUR by HSBC in a report announced 8/16/2016. The increased target price indicates a potential upside of 0.06% based on the company’s previous closing price.
Previously on 8/15/2016, Deutsche Bank AG released a statement on Carl Zeiss Meditec(ETR:AFX) raised the target price from 0.00EUR to 31.00EUR. At the time, this indicated a possible downside of -0.08%.
Only yesterday Carl Zeiss Meditec (ETR:AFX) traded 0.00% even at 33.83EUR. AFX’s 50-day moving average is 0.00EUR and its 200-day average is 0.00EUR. The last stock price is up 0.00% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the date range. 0 shares of Carl Zeiss Meditec traded hands, from ann avg. trading volume of 0.
Recent Performance Chart:
Carl Zeiss Meditec has a 52 week low of 0.00EUR and a 52 week high of 0.00EUR and has a market capitalization of 0.0 EUR.
Brief Synopsis About Carl Zeiss Meditec (ETR:AFX)
Carl Zeiss Meditec AG is a Germany-based medical technology solutions supplier. The Company operates, along with its subsidiaries, in two business areas: Ophthalmology and Microsurgery. The Ophthalmology business area is subdivided into two business units: the Ophthalmology systems unit covers a range of laser and diagnostic systems for ophthalmology, and the Surgical Ophthalmology unit combines the Company’s activities in the field of ophthalmic implants and disposables. The Microsurgery business area offers surgical microscopes and visualization solutions for ear, nose and throat surgery, or neurosurgery. Its microsurgery products are mainly used as supporting equipment for the removal of tumors, as well as the treatment of vascular diseases and functional disorders. In January 2014, it acquired Optronik Optik ve Elektronik Cihazlar Ticaret ve Sanayi AS, a wholesaler of ophthalmology products, as well as a 100% stake in Aaren Scientific Inc, and a producer of intraocular lenses.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.